Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04341181 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | PHASE2 | RECRUITING | 300 | — | — | Aug 24, 2020 | Apr 30, 2030 | Jul 25, 2025 | 7 | Denmark |
Response according to RECIST
| Arm | Type | Description |
|---|---|---|
| Alectinib | EXPERIMENTAL | Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib. |
| Atezolizumab | EXPERIMENTAL | Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab. |
| Avelumab | EXPERIMENTAL | Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab. |
| Axitinib | EXPERIMENTAL | Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib. |
| Erlotinib | EXPERIMENTAL | Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib. |
| Vemurafenib plus Cobimetinib (combination) | EXPERIMENTAL | Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib. |
| Trastuzumab plus Pertuzumab (combination) | EXPERIMENTAL | Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab. |
| Trastuzumab emtansin | EXPERIMENTAL | Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin. |
| Vismodegib | EXPERIMENTAL | Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib. |
| Niraparib | EXPERIMENTAL | Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib. |
| Name | Type | Description |
|---|---|---|
| Alectinib | DRUG | Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile. |
| Atezolizumab | DRUG | Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile. |
| Avelumab | DRUG | Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile. |
| Axitinib | DRUG | Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile. |
| Erlotinib | DRUG | Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile. |
| Vemurafenib plus Cobimetinib (combination) | DRUG | Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile. |
| Trastuzumab plus Pertuzumab (combination) | DRUG | Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile. |
| Trastuzumab emtansine | DRUG | Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile. |
| Vismodegib | DRUG | Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile. |
| Niraparib | DRUG | Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile. |
Inclusion Criteria: 1. Patient (age≥ 18 years) with a histologically-proven locally advanced or metastatic malignant disease who is no longer benefitting from standard anti-cancer treatment or for whom, in the opinion of the investigator, no such treatment is available or indicated. 2. ECOG perform...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |